Introduction: The demand for intravitreal therapy has increased dramatically with the introduction of vascular endo-thelial growth factor inhibitors. Improved utilisation of existing resources is crucial to meeting the increased future demand. We investigated time spent preparing intravitreal injection treatment using either prefilled syringes or vials in routine clinical practice.
Methods: We video-recorded preparations of intravitreal injections (n = 172) for each preparation type (ranibizumab prefilled syringe (n = 56), ranibizumab vial (n = 56) and aflibercept vial (n = 60)) in a multi-centre time and motion study. The preparation times for each step were extracted from videos and the three preparation types were compared.
Results: Prefilled syringes eliminated several steps in the preparation process. Total preparation time was 40.3-45.1 sec. using vials, and the use of prefilled syringes saved 25.5 sec. (95% confidence interval (CI): 23.3-27.6 sec., p < 0.0001). The preparation time when aflibercept vials were used was 3.7 sec. (95% CI: 1.45-5.96 sec., p = 0.0014) longer than when ranibizumab vials were used.
Conclusions: Prefilled syringes for intravitreal injections reduce preparation time by eliminating preparation steps that both entail a risk of contamination and are subject to variation. The amount of time saved may enable increased utilisation of existing resources and outsourcing to non-ophthalmologists.
Funding: This study was supported by a grant from Novartis. The funders had no influence on the design of the study, analysis of the data, preparation of the manuscript or the decision to publish.
Trial Registration: not relevant.
Download full-text PDF |
Source |
---|
Eur J Hosp Pharm
January 2025
Pharmacy Department, Lausanne University Hospital, Lausanne, Switzerland
Background: Intravitreal and intracameral administration of melphalan and topotecan (TPT) has shown its efficacy in the treatment of retinoblastoma over the last few years. Due to rapid hydrolysis, melphalan must be administered within the hour following reconstitution. With improved stability at room temperature and reduced ocular toxicity, TPT seems to be a promising candidate for production of prefilled syringes in terms of safety and efficiency of preparation and treatment administration.
View Article and Find Full Text PDFOphthalmologie
January 2025
Augenklinik Petrisberg, Max-Planck-Str. 14-16, 54296, Trier, Deutschland.
Expert Rev Clin Immunol
January 2025
Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
Background: CT-P47 is a candidate tocilizumab biosimilar that is currently in clinical development. We assessed the usability of CT-P47 self-administration via auto-injector (AI) in patients with rheumatoid arthritis (RA).
Research Design And Methods: This was a 12-week, single-arm, open-label, multiple-dose, Phase 3 study.
Mol Pharm
January 2025
Drug Product Development-Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, United States.
Therapeutic monoclonal antibody (mAb) drug products are increasingly used to treat both chronic and acute diseases. These mAb drug products are often developed for subcutaneous (SC) injection to simplify dosing compared with intravenous (IV) infusion. For SC injection, the mAb liquid drug product is typically filled in a vial for use with a syringe or in a prefilled syringe, which can then be assembled into a safety syringe device or an autoinjector for direct administration.
View Article and Find Full Text PDFInfect Dis Clin Microbiol
December 2024
Department of Pediatric Intensive Care Unit, Dr. Behçet Uz Children's Diseases and Surgery Training and Research Hospital, İzmir, Türkiye.
Objective: We aimed to discuss our experience of a higher incidence of catheter-associated bloodstream infections (CLABSIs) during the needle-free connector (NFC) and single-use prefilled flushing syringe (PFS) shortage.
Materials And Methods: Retrospective analyses were carried out to investigate the CLABSI rates at a tertiary training hospital from January 1, 2023, to December 31, 2023, and the study period included a three-month shortage of NFCs and PFSs in April and June 2023.
Results: The CLABSI rate for the three months was 5.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!